Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5184200
Max Phase: Preclinical
Molecular Formula: C61H89N11O14S2
Molecular Weight: 1264.58
Associated Items:
ID: ALA5184200
Max Phase: Preclinical
Molecular Formula: C61H89N11O14S2
Molecular Weight: 1264.58
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCSC)C(=O)O)C(C)C
Standard InChI: InChI=1S/C61H89N11O14S2/c1-10-35(6)51(72-53(77)42(62)29-37-14-12-11-13-15-37)60(84)64-36(7)52(76)67-45(28-33(2)3)55(79)69-48(32-49(63)75)58(82)68-46(30-38-16-20-40(73)21-17-38)56(80)65-43(24-26-87-8)54(78)71-50(34(4)5)59(83)70-47(31-39-18-22-41(74)23-19-39)57(81)66-44(61(85)86)25-27-88-9/h11-23,33-36,42-48,50-51,73-74H,10,24-32,62H2,1-9H3,(H2,63,75)(H,64,84)(H,65,80)(H,66,81)(H,67,76)(H,68,82)(H,69,79)(H,70,83)(H,71,78)(H,72,77)(H,85,86)/t35-,36-,42-,43-,44-,45-,46-,47-,48-,50-,51-/m0/s1
Standard InChI Key: ROJNAPSBPWYSLE-LUMLJNENSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1264.58 | Molecular Weight (Monoisotopic): 1263.6032 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Yoshida J, Takayama K, Kawada M.. (2022) Short peptides derived from hGAPDH exhibit anti-cancer activity., 71 [PMID:35964520] [10.1016/j.bmc.2022.116953] |
Source(1):